drugset / Trial / NCT07307586

A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B

NCT07307586

Phase 3 Recruiting 120 enrolled Zhigang Ren
RandomizedParallel-groupSingle-blindTreatment

Summary

Through regular monitoring of viral load, liver function and immune cell activity, the long-term efficacy of Adefovir in controlling HBV is precisely evaluated. By employing a dual mechanism of "antiviral action plus immune activation", it offers a novel therapeutic option for achieving clinical cure in chronic hepatitis B.

Timeline

Start
2025-09-01
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Azvudine Small molecule
Comparator IFNα-2a Protein / enzyme biologic
Comparator TAF Unknown